CTOR
Citius Oncology Inc.

1,357
Mkt Cap
$47.76M
Volume
189,427.00
52W High
$6.19
52W Low
$0.52
PE Ratio
-1.76
CTOR Fundamentals
Price
$0.541
Prev Close
$0.578
Open
$0.58
50D MA
$1.01
Beta
-2.43
Avg. Volume
148,956.72
EPS (Annual)
-$0.338
P/B
0.79
$148.61
Loading...
Loading...
News
all
press releases
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...
PR Newswire·3d ago
News Placeholder
More News
News Placeholder
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Here's What Happened
Citius Oncology (NASDAQ:CTOR) Stock Price Down 2.8% - Time to Sell...
MarketBeat·3d ago
News Placeholder
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology...
PR Newswire·17d ago
News Placeholder
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·23d ago
News Placeholder
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update
Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling...
MarketBeat·25d ago
News Placeholder
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates
Citius Oncology (NASDAQ:CTOR - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of...
MarketBeat·1mo ago
News Placeholder
Citius Oncology Q1 Earnings Summary & Key Takeaways
read more...
Benzinga·1mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...
PR Newswire·1mo ago
News Placeholder
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...
PR Newswire·1mo ago
News Placeholder
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...
PR Newswire·1mo ago
<
1
2
...
>

Latest CTOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.